Former senior executive at JenaValve Technology Inc
- Major trends and developments in the heart valve replacement space, focusing on AR (aortic regurgitation) and AS (aortic stenosis)
- Core value proposition and differentiation of JenaValve’s Trilogy device
- Conclusion of ALIGN-AR clinical trial and preparation for US commercial product launch
- Long-term growth strategy and untapped market opportunities
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.